OCT Analysis of Very Early Strut Coverage of the Synergy Stent in Non-ST Segment Elevation Acute Coronary Syndrome Patients.
Acute Coronary Syndrome
/ diagnostic imaging
Aged
Aged, 80 and over
Angioplasty, Balloon, Coronary
/ instrumentation
Coronary Angiography
/ methods
Coronary Restenosis
/ diagnostic imaging
Drug-Eluting Stents
Everolimus
/ pharmacology
Female
Follow-Up Studies
Humans
Male
Middle Aged
Myocardial Infarction
/ diagnostic imaging
Neointima
/ diagnostic imaging
Prospective Studies
Prosthesis Design
Risk Assessment
Time Factors
Tomography, Optical Coherence
/ methods
Treatment Outcome
acute coronary syndrome
drug-eluting stent
optical coherence tomography
Journal
The Journal of invasive cardiology
ISSN: 1557-2501
Titre abrégé: J Invasive Cardiol
Pays: United States
ID NLM: 8917477
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
pubmed:
13
11
2018
medline:
18
12
2019
entrez:
13
11
2018
Statut:
ppublish
Résumé
Early endothelialization of drug-eluting stent (DES) is a major challenge to reduce the risk of stent thrombosis and the duration of dual-antiplatelet therapy (DAPT) in high bleeding-risk patients. The aim of the present study is to evaluate very early strut coverage with optical coherence tomography (OCT) of the Synergy stent (Boston Scientific) at 1 month in non-ST segment elevation acute coronary syndrome (NSTE-ACS) patients. This substudy of the EARLY trial prospectively included NSTE-ACS patients treated with the Synergy DES. OCT analysis of the Synergy stent was performed during a staged PCI of additional lesions at 1 month. The primary endpoint was the percentage of covered struts assessed with OCT at 1 month. Twenty-four patients were included, with a mean stent length of 35.9 ± 10.1 mm per patient. The rate of covered struts was 78.5% out of 3839 struts analyzed. Nineteen patients (79.2%) had at least 70% of their struts covered. The average neointimal thickness was 0.0508 ± 0.016 mm. In NSTE-ACS patients undergoing culprit percutaneous coronary intervention with the Synergy stent, the rate of covered struts at 1 month was 78.5%. This rapid coverage is in line with the results of clinical trials demonstrating the safety of short-duration DAPT in selected patients who are at high bleeding risk and treated with new-generation DES options.
Substances chimiques
Everolimus
9HW64Q8G6G
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM